Paul E Keck

Summary

Publications

  1. ncbi Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression
    Paul E Keck
    Psychopharmacology Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA
    J Clin Psychiatry 66:611-6. 2005
  2. ncbi Mixed hypomania in 908 patients with bipolar disorder evaluated prospectively in the Stanley Foundation Bipolar Treatment Network: a sex-specific phenomenon
    Trisha Suppes
    Bipolar Disorder Research Program, Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas 75390 9121, USA
    Arch Gen Psychiatry 62:1089-96. 2005
  3. ncbi A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders
    Susan L McElroy
    Psychopharmacology Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45267 0559, USA
    Bipolar Disord 9:426-34. 2007
  4. ncbi Open-label aripiprazole in the treatment of acute bipolar depression: a prospective pilot trial
    Susan L McElroy
    Psychopharmacology Research Program, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States
    J Affect Disord 101:275-81. 2007
  5. ncbi Impact of antidepressant continuation after acute positive or partial treatment response for bipolar depression: a blinded, randomized study
    Lori L Altshuler
    Department of Psychiatry, Veterans Affairs Greater Los Angeles Healthcare System, West Los Angeles Healthcare Center, Los Angeles, CA, USA
    J Clin Psychiatry 70:450-7. 2009
  6. ncbi Quetiapine for the continuation treatment of bipolar depression: naturalistic prospective case series from the Stanley Bipolar Treatment Network
    Trisha Suppes
    Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9121, USA
    Int Clin Psychopharmacol 22:376-81. 2007
  7. ncbi Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo
    Paul E Keck
    Psychopharmacology Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267 0559, USA
    J Clin Psychiatry 68:1480-91. 2007
  8. ncbi Open-label adjunctive zonisamide in the treatment of bipolar disorders: a prospective trial
    Susan L McElroy
    Psychopharmacology Research Program, Department of Psychiatry, PO Box 670559, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267, USA
    J Clin Psychiatry 66:617-24. 2005
  9. ncbi Subsyndromal depressive symptoms are associated with functional impairment in patients with bipolar disorder: results of a large, multisite study
    Lori L Altshuler
    Department of Psychiatry, VA Greater Los Angeles Healthcare System, West Los Angeles Healthcare Center, CA, USA
    J Clin Psychiatry 67:1551-60. 2006
  10. ncbi Ethnicity and first-rank symptoms in patients with psychosis
    Lesley M Arnold
    Bipolar and Psychotic Disorders Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45267 0559, USA
    Schizophr Res 67:207-12. 2004

Collaborators

Detail Information

Publications106 found, 100 shown here

  1. ncbi Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression
    Paul E Keck
    Psychopharmacology Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA
    J Clin Psychiatry 66:611-6. 2005
    ..These subanalyses compare treatment-emergent mania rates in bipolar I depressed patients treated with olanzapine, placebo, or olanzapine/fluoxetine combination...
  2. ncbi Mixed hypomania in 908 patients with bipolar disorder evaluated prospectively in the Stanley Foundation Bipolar Treatment Network: a sex-specific phenomenon
    Trisha Suppes
    Bipolar Disorder Research Program, Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas 75390 9121, USA
    Arch Gen Psychiatry 62:1089-96. 2005
    ..The prevalence of depressive symptoms co-occurring with hypomanic symptoms has not been quantified. Whether there is a greater likelihood for women to experience mixed symptoms has not been resolved...
  3. ncbi A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders
    Susan L McElroy
    Psychopharmacology Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45267 0559, USA
    Bipolar Disord 9:426-34. 2007
    ..The objective of this study was to compare sibutramine and topiramate as adjunctive treatments for psychotropic-associated weight gain in overweight or obese outpatients with BD...
  4. ncbi Open-label aripiprazole in the treatment of acute bipolar depression: a prospective pilot trial
    Susan L McElroy
    Psychopharmacology Research Program, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States
    J Affect Disord 101:275-81. 2007
    ..Increasing evidence indicates that some second-generation antipsychotics are efficacious in bipolar depression, but there are few data on this illness for the novel agent aripiprazole...
  5. ncbi Impact of antidepressant continuation after acute positive or partial treatment response for bipolar depression: a blinded, randomized study
    Lori L Altshuler
    Department of Psychiatry, Veterans Affairs Greater Los Angeles Healthcare System, West Los Angeles Healthcare Center, Los Angeles, CA, USA
    J Clin Psychiatry 70:450-7. 2009
    ..To assess long-term outcome in bipolar disorder, subjects were prospectively followed after receiving acute treatment for bipolar depression...
  6. ncbi Quetiapine for the continuation treatment of bipolar depression: naturalistic prospective case series from the Stanley Bipolar Treatment Network
    Trisha Suppes
    Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9121, USA
    Int Clin Psychopharmacol 22:376-81. 2007
    ..No between-group differences in improvement were found. Adjunctive quetiapine may be useful as continuation treatment in bipolar populations with both pure depressive and cycling symptoms. Further controlled studies are warranted...
  7. ncbi Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo
    Paul E Keck
    Psychopharmacology Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267 0559, USA
    J Clin Psychiatry 68:1480-91. 2007
    ..Efficacy and tolerability of aripiprazole for relapse prevention in bipolar I disorder was, therefore, evaluated for 100 weeks...
  8. ncbi Open-label adjunctive zonisamide in the treatment of bipolar disorders: a prospective trial
    Susan L McElroy
    Psychopharmacology Research Program, Department of Psychiatry, PO Box 670559, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267, USA
    J Clin Psychiatry 66:617-24. 2005
    ..The response of 62 outpatients with DSM-IV bipolar disorders to open-label adjunctive zonisamide was evaluated in a prospective 8-week acute trial, followed by a 48-week continuation trial, conducted from June 2001 through May 2002...
  9. ncbi Subsyndromal depressive symptoms are associated with functional impairment in patients with bipolar disorder: results of a large, multisite study
    Lori L Altshuler
    Department of Psychiatry, VA Greater Los Angeles Healthcare System, West Los Angeles Healthcare Center, CA, USA
    J Clin Psychiatry 67:1551-60. 2006
    ..Research examining this relationship in persons with bipolar disorder is rare. This study sought to evaluate the association between subsyndromal depressive symptoms and role functioning in subjects with bipolar disorder...
  10. ncbi Ethnicity and first-rank symptoms in patients with psychosis
    Lesley M Arnold
    Bipolar and Psychotic Disorders Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45267 0559, USA
    Schizophr Res 67:207-12. 2004
    ..These findings indicate that psychotic symptom presentation should be evaluated in the context of other symptoms (e.g., affective symptoms) in diagnostic assessments in order to prevent misdiagnoses of schizophrenia...
  11. ncbi Topiramate in the long-term treatment of binge-eating disorder associated with obesity
    Susan L McElroy
    Psychopharmacology Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267 0559, USA
    J Clin Psychiatry 65:1463-9. 2004
    ..This study assessed the long-term effectiveness and tolerability of topiramate in binge-eating disorder (BED) with obesity...
  12. ncbi Effects of co-occurring alcohol abuse on the course of bipolar disorder following a first hospitalization for mania
    Stephen M Strakowski
    Division of Bipolar Disorders Research, University of Cincinnati College of Medicine, 231 Albert Sabin Way ML0559, PO Box 670559, Cincinnati, OH 45267 0559, USA
    Arch Gen Psychiatry 62:851-8. 2005
    ..Alcohol-use disorders are common co-occurring conditions affecting bipolar patients, and this co-occurrence is negatively associated with outcome...
  13. pmc Characterizing impulsivity in mania
    Stephen M Strakowski
    Division of Bipolar Disorders Research, Universtiy of Cincinnati College of Medicine, Cincinnati, OH, USA
    Bipolar Disord 11:41-51. 2009
    ....
  14. doi Correlates of treatment-emergent mania associated with antidepressant treatment in bipolar depression
    Mark A Frye
    Department of Psychiatry, Mayo Mood Clinic and Research Program, Mayo Clinic, 200 First St, S W, Rochester, MN 55901, USA
    Am J Psychiatry 166:164-72. 2009
    ..This study examined the correlates associated with treatment-emergent mania in patients receiving adjunctive antidepressant treatment for bipolar depression...
  15. ncbi Effects of co-occurring cannabis use disorders on the course of bipolar disorder after a first hospitalization for mania
    Stephen M Strakowski
    Division of Bipolar Disorders Research, Department of Psychiatry, University of Cincinnati College of Medicine, 2341 Albert Sabin Way, Cincinnati, OH 45267, USA
    Arch Gen Psychiatry 64:57-64. 2007
    ..Cannabis use disorders commonly co-occur in bipolar disorder; however, the effects of cannabis abuse on outcome have been minimally studied...
  16. ncbi Psychosis in bipolar disorder: phenomenology and impact on morbidity and course of illness
    Paul E Keck
    Department of Psychiatry, University of Cincinnati College of Medicine, OH 45267 0559, USA
    Compr Psychiatry 44:263-9. 2003
    ..The lack of observable prognostic impact may have been, in part, due to the relatively high morbidity and poor functional outcome of a substantial portion of the total cohort...
  17. ncbi The role of second-generation antipsychotic monotherapy in the rapid control of acute bipolar mania
    Paul E Keck
    Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, USA
    J Clin Psychiatry 66:5-11. 2005
    ..Therefore, selecting a second-generation antipsychotic requires consideration of how an agent's efficacy, onset of action, and adverse events profile influence its appropriateness for each patient...
  18. doi Lamotrigine in the treatment of binge-eating disorder with obesity: a randomized, placebo-controlled monotherapy trial
    Anna I Guerdjikova
    Department of Psychiatry, University of Cincinnati College of Medicine, Lindner Center of HOPE, Mason, Ohio 45040, USA
    Int Clin Psychopharmacol 24:150-8. 2009
    ..As a result of an exceptionally high placebo response, it is likely that for efficacy measures except for body weight and metabolic indices, the study was incapable of detecting potentially clinically important drug-placebo difference...
  19. pmc Suggestive evidence for association of the circadian genes PERIOD3 and ARNTL with bipolar disorder
    Caroline M Nievergelt
    Department of Psychiatry, University of California, San Diego, La Jolla, California 92093 0603, USA
    Am J Med Genet B Neuropsychiatr Genet 141:234-41. 2006
    ..However, the trends for ARNTL and PER3 are suggestive of their involvement in bipolar disorder and warrant further study in a larger sample...
  20. doi Treatment costs and health care utilization for patients with bipolar disorder in a large managed care population
    Jeff J Guo
    College of Pharmacy, University of Cincinnati Medical Center, Cincinnati, OH, USA
    Value Health 11:416-23. 2008
    ....
  21. ncbi Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder
    Paul E Keck
    Psychopharmacology Research Program, Department of Psychiatry, University of Cincinnati College of Medicine and the Mental Health Care Line, Cincinnati, Ohio 45267 0559, USA
    Biol Psychiatry 60:1020-2. 2006
    ..The results of pilot trials suggest that omega-3 fatty acids may have efficacy in the treatment of mood symptoms in bipolar disorder...
  22. ncbi Comorbidity of fibromyalgia and psychiatric disorders
    Lesley M Arnold
    Women s Health Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, Ohio 45219, USA
    J Clin Psychiatry 67:1219-25. 2006
    ..To assess the co-occurrence of fibromyalgia with psychiatric disorders in participants of a fibromyalgia family study...
  23. ncbi Citalopram in the treatment of binge-eating disorder: a placebo-controlled trial
    Susan L McElroy
    Division of Psychopharmacology Research and Eating Disorders, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267 0559, USA
    J Clin Psychiatry 64:807-13. 2003
    ..Citalopram is a highly selective serotonin reuptake inhibitor antidepressant. The purpose of this study was to assess the efficacy and safety of citalopram in the treatment of binge-eating disorder...
  24. ncbi Treatment costs related to bipolar disorder and comorbid conditions among Medicaid patients with bipolar disorder
    Jeff J Guo
    Division of Pharmacy Practice and Administrative Sciences, College of Pharmacy and the Institute for the Study of Health, University of Cincinnati Academic Health Center, 3225 Eden Avenue, Cincinnati, OH 45267 0004, USA
    Psychiatr Serv 58:1073-8. 2007
    ..This study assessed costs among patients with bipolar disorder for treatment related to bipolar disorder and to comorbid conditions. Risk factors associated with costs were also assessed...
  25. ncbi Comorbidity of bipolar and eating disorders: distinct or related disorders with shared dysregulations?
    Susan L McElroy
    Psychopharmacology Research Program, University of Cincinnati College of Medicine, P O Box 670559, 231 Bethesda Avenue, Cincinnati, OH 45267 0559, USA
    J Affect Disord 86:107-27. 2005
    ..The co-occurrence of bipolar and eating disorders, though of major clinical and public health importance, remains relatively unexamined...
  26. ncbi Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial
    Susan L McElroy
    Psychopharmacology Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, OH 45267 0559, USA
    J Clin Psychiatry 67:1897-906. 2006
    ..Binge eating disorder (BED) is associated with obesity. Zonisamide is a novel antiepileptic drug associated with weight loss. The purpose of this study was to evaluate zonisa-mide in the treatment of BED associated with obesity...
  27. ncbi Are mood disorders and obesity related? A review for the mental health professional
    Susan L McElroy
    Psychopharmacology Research and Eating Disorders and Obesity Research and Treatment Programs, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267 0559, USA
    J Clin Psychiatry 65:634-51, quiz 730. 2004
    ..We reviewed evidence regarding a possible relationship between mood disorders and obesity to better inform mental health professionals about their overlap...
  28. ncbi Tiagabine in treatment refractory bipolar disorder: a clinical case series
    Trisha Suppes
    Department of Psychiatry, The University of Texas Southwestern Medical Center, Dallas, TX 75390 9070, USA
    Bipolar Disord 4:283-9. 2002
    ..We sought to evaluate the effectiveness of tiagabine added to ongoing medication regimens in patients with bipolar disorder inadequately responsive to or intolerant of usual treatments...
  29. ncbi Maintenance efficacy of divalproex in the prevention of bipolar depression
    Laszlo Gyulai
    Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA
    Neuropsychopharmacology 28:1374-82. 2003
    ....
  30. pmc Further evidence for linkage of bipolar disorder to chromosomes 6 and 17 in a new independent pedigree series
    Tiffany A Greenwood
    Department of Psychiatry, University of California, San Diego, CA, USA
    Bipolar Disord 14:71-9. 2012
    ..We now report the results of our genome-wide linkage analysis in an independent sample of 34 pedigrees segregating bipolar disorder...
  31. ncbi Factors associated with medication adherence in African American and white patients with bipolar disorder
    David E Fleck
    Center for Bipolar Disorders Research, Department of Psychiatry, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267, USA
    J Clin Psychiatry 66:646-52. 2005
    ..The purpose of this study was to examine rates of medication nonadherence, self-perceived reasons for nonadherence, and attitudes associated with non-adherence in these ethnic groups...
  32. doi Incidence of childhood-onset bipolar illness in the USA and Europe
    Robert M Post
    Department of Psychiatry, George Washington University, Washington, DC, USA
    Br J Psychiatry 192:150-1. 2008
    ..In the USA there was also twice the incidence of childhood adversity and genetic/familial risk for affective disorder. The findings deserve replication and further exploration...
  33. ncbi Defining and improving response to treatment in patients with bipolar disorder
    Paul E Keck
    Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA
    J Clin Psychiatry 65:25-9. 2004
    ..Psychoeducation for patients and families and interpersonal psychotherapy also can help prolong remission...
  34. ncbi Lithium augmentation of topiramate for bipolar disorder with comorbid binge eating disorder and obesity
    Renu Kotwal
    Department of Psychiatry, Psychopharmacology Research Program, University of Cincinnati College of Medicine, Cincinnati, OH 45267 0559, USA
    Hum Psychopharmacol 21:425-31. 2006
    ..To evaluate the effectiveness of lithium augmentation of topiramate on mood symptoms, binge eating behavior, and body weight in obese bipolar patients with binge eating disorder (BED) seeking weight management...
  35. ncbi A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder
    Paul E Keck
    Psychopharmacology Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, USA
    J Clin Psychiatry 67:626-37. 2006
    ..To investigate the safety and efficacy of aripiprazole in preventing relapse of a mood episode in recently manic- or mixed-episode patients with bipolar I disorder stabilized on aripiprazole...
  36. ncbi Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: a nested case-control study
    Jeff J Guo
    College of Pharmacy, University of Cincinnati Medical Center, Cincinnati, Ohio 45267 0004, USA
    Pharmacotherapy 27:27-35. 2007
    ..To quantify the risk of diabetes mellitus associated with atypical antipsychotics compared with conventional antipsychotics in managed care Medicaid patients with bipolar disorder...
  37. ncbi Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial
    Paul E Keck
    Department of Psychiatry, University of Cincinnati College of Medicine, OH 45627 0559, USA
    Am J Psychiatry 160:741-8. 2003
    ..The study evaluated the efficacy and tolerability of ziprasidone, compared with placebo, in the treatment of adult patients with acute bipolar mania...
  38. ncbi Pharmacologic treatment considerations in co-occurring bipolar and anxiety disorders
    Paul E Keck
    Psychopharmacology Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, OH 45267 0559, USA
    J Clin Psychiatry 67:8-15. 2006
    ..Anxiety disorders are among the most commonly co-occurring psychiatric syndromes with bipolar disorder. The presence of co-occurring anxiety disorders has important prognostic and treatment implications...
  39. pmc Heritability and genome-wide SNP linkage analysis of temperament in bipolar disorder
    Tiffany A Greenwood
    Department of Psychiatry, University of California San Diego, La Jolla, CA 92093, USA
    J Affect Disord 150:1031-40. 2013
    ....
  40. pmc Association of dopamine transporter gene variants with childhood ADHD features in bipolar disorder
    Tiffany A Greenwood
    Department of Psychiatry, University of California San Diego, La Jolla, CA 92093, USA
    Am J Med Genet B Neuropsychiatr Genet 162:137-45. 2013
    ..002, 0.007, and 8 × 10(-4), respectively). These data suggest that variants within DAT1 may predispose to a subtype of BD characterized by early prodromal features that include attentional deficits...
  41. ncbi Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial
    Susan L McElroy
    Psychopharmacology Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, OH 45267 0559, USA
    J Clin Psychiatry 68:390-8. 2007
    ..Binge-eating disorder (BED) is associated with obesity. Atomoxetine is a highly selective norepinephrine reuptake inhibitor associated with weight loss. The purpose of this study was to evaluate atomoxetine in the treatment of BED...
  42. ncbi A placebo-controlled, randomized trial of fluoxetine in the treatment of binge-eating disorder
    Lesley M Arnold
    Women s Health Research Program, Department of Psychiatry, University of Cincinnati Medical Center, Cincinnati, Ohio, USA
    J Clin Psychiatry 63:1028-33. 2002
    ..The purpose of this study was to assess the efficacy and safety of fluoxetine in the treatment of binge-eating disorder...
  43. ncbi High-dose escitalopram in the treatment of binge-eating disorder with obesity: a placebo-controlled monotherapy trial
    Anna I Guerdjikova
    Division of Psychopharmacology Research, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267 0559, USA
    Hum Psychopharmacol 23:1-11. 2008
    ..The purpose of this study was to evaluate the efficacy and safety of high-dose escitalopram in the treatment of binge-eating disorder (BED) associated with obesity...
  44. ncbi Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial
    Susan L McElroy
    Division of Psychopharmacology Research, Department of Psychiatry, University of Cincinnati College of Medicine, OH 45267 0559, USA
    Am J Psychiatry 160:255-61. 2003
    ..Binge eating disorder is associated with obesity. Topiramate is an antiepileptic agent associated with weight loss. The objective of this study was to evaluate topiramate in the treatment of binge eating disorder associated with obesity...
  45. ncbi Relationship of open acute mania treatment to blinded maintenance outcome in bipolar I disorder
    Susan L McElroy
    Psychopharmacology Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45267 0559, USA
    J Affect Disord 107:127-33. 2008
    ..No published studies have statistically evaluated the relationship between the outcomes in maintenance treatment and the principal acute agent...
  46. ncbi New approaches in managing bipolar depression
    Paul E Keck
    Program Psychopharmacology Research, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267 0559, USA
    J Clin Psychiatry 64:13-8. 2003
    ....
  47. ncbi Placebo response in binge eating disorder: a pooled analysis of 10 clinical trials from one research group
    Thomas J Blom
    Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA Lindner Center of HOPE, Mason, OH, USA
    Eur Eat Disord Rev 22:140-6. 2014
    ..The aim of this study was to gain further understanding of placebo response in binge eating disorder...
  48. ncbi Examination of the clock gene Cryptochrome 1 in bipolar disorder: mutational analysis and absence of evidence for linkage or association
    Caroline M Nievergelt
    Department of Psychiatry, University of California, San Diego, La Jolla, CA 92093, USA
    Psychiatr Genet 15:45-52. 2005
    ..Additional, more powerful, studies involving Cry1 and other circadian clock genes need to be tested before an association of circadian abnormalities with bipolar disorder can be excluded...
  49. ncbi Long-term therapy of bipolar illness
    Paul E Keck
    University of Cincinnati College of Medicine, USA
    J Fam Pract . 2003
  50. ncbi Comorbidity of eating disorders with bipolar disorder and treatment implications
    Susan L McElroy
    Psychopharmacology Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267, USA
    Bipolar Disord 8:686-95. 2006
    ..To review the scientific evidence examining the comorbidity among eating disorders and bipolar disorder (BD)...
  51. doi Are bipolar mood symptoms affected by the phase of the menstrual cycle?
    Geetha Shivakumar
    Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9086, USA
    J Womens Health (Larchmt) 17:473-8. 2008
    ..We sought to examine the relationship between bipolar disorder and menstrual cycle-related mood changes. To our knowledge, this is one of the largest samples in the literature addressing this issue...
  52. ncbi Long-term safety and efficacy of ziprasidone in subpopulations of patients with bipolar mania
    Paul E Keck
    Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45267 0559, USA
    J Clin Psychiatry 70:844-51. 2009
    ..To evaluate long-term safety and efficacy of ziprasidone...
  53. ncbi Psychiatric and metabolic characteristics of childhood versus adult-onset obesity in patients seeking weight management
    Anna I Guerdjikova
    Psychopharmacology Program, Department of Psychiatry, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267 0559, USA
    Eat Behav 8:266-76. 2007
    ..Early recognition and attention to eating and mood dysregulation, including, but not limited to binge eating disorder and bulimia nervosa, in some persons, might help reduce their lifetime risk for obesity...
  54. ncbi Suggestive linkage of a chromosomal locus on 18p11 to cyclothymic temperament in bipolar disorder families
    Lynn M Evans
    Department of Psychiatry, Columbia University, New York, New York, USA
    Am J Med Genet B Neuropsychiatr Genet 147:326-32. 2008
    ..The temperament-based cyclothymic trait yielded a higher peak LOD score and a lower P-value than analyses using traditional, categorical phenotypes in a separate analysis including these same families...
  55. ncbi A retrospective chart review of intramuscular ziprasidone for agitation in children and adolescents on psychiatric units: prospective studies are needed
    Drew H Barzman
    Children s Hospital Medical Center, Division of Child and Adolescent Psychiatry, Cincinnati, Ohio 45229 3039, USA
    J Child Adolesc Psychopharmacol 17:503-9. 2007
    ..Our secondary objective was to examine demographic and clinical factors associated with treatment response...
  56. doi Exposure to potentially dangerous drug-drug interactions involving antipsychotics
    Jeff Jianfei Guo
    Division of Pharmacy Practice and Administrative Sciences, College of Pharmacy, University of Cincinnati Medical Center, 3225 Eden Ave, Cincinnati, OH 45267, USA
    Psychiatr Serv 63:1080-8. 2012
    ..This study used a large state's Medicaid claims database to examine the proportion of patients exposed to such interactions and the risk factors associated with exposure...
  57. ncbi Phenomenology associated with age at onset in patients with bipolar disorder at their first psychiatric hospitalization
    Nick C Patel
    College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267 0004, USA
    Bipolar Disord 8:91-4. 2006
    ..To compare the clinical presentation of patients with early-onset (age <18 years) and typical-onset (age 20-30 years) bipolar disorder at the time of first hospitalization...
  58. ncbi Ethnic differences in maintenance antipsychotic prescription among adolescents with bipolar disorder
    Nick C Patel
    Department of Psychiatry, University of Cincinnati, and the General Clinical Research Center and Mental Health Service Line, Cincinnati Veterans Affairs Medical Center, Ohio 45267 0004, USA
    J Child Adolesc Psychopharmacol 15:938-46. 2005
    ..The aim of this study was to compare the longitudinal use of psychotropic medications in African-American and Caucasian adolescents with a diagnosis of bipolar disorder following their first psychiatric hospitalization...
  59. ncbi Olanzapine in the treatment of pathological gambling: a negative randomized placebo-controlled trial
    Susan L McElroy
    Psychopharmacology Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267 0559, USA
    J Clin Psychiatry 69:433-40. 2008
    ..Olanzapine is a second-generation antipsychotic with mood-stabilizing properties and antagonistic activity at several dopamine receptors. The purpose of this study was to evaluate olanzapine in the treatment of pathological gambling...
  60. ncbi Familiality of temperament in bipolar disorder: support for a genetic spectrum
    Lynn Evans
    Department of Psychiatry, UCSD, School of Medicine, University of California, 9500 Gilman Drive, La Jolla, CA 92093 0603, USA
    J Affect Disord 85:153-68. 2005
    ..We predicted that a gradient of scores would be observed from those with BP to those with major depression to unaffected relatives to controls...
  61. ncbi Zonisamide in the treatment of binge-eating disorder: an open-label, prospective trial
    Susan L McElroy
    Division of Clinical Neuroscience, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA
    J Clin Psychiatry 65:50-6. 2004
    ..It commonly co-occurs with obesity. Zonisamide is a novel antiepileptic drug associated with weight loss. The purpose of this study was to preliminarily assess zonisamide in the treatment of binge-eating disorder...
  62. doi Suggestive evidence for linkage of ADHD features in bipolar disorder to chromosome 10p14
    Eun Jeong Joo
    Department of Psychiatry, University of California, San Diego, La Jolla, California, USA
    Am J Med Genet B Neuropsychiatr Genet 153:260-8. 2010
    ..10p14, in particular may contain a locus for inattention in bipolar disorder. Quantitative dimensional phenotypes such as this may be useful for both mapping of genes and understanding the role of genes in bipolar disorder...
  63. ncbi Long-term management strategies to achieve optimal function in patients with bipolar disorder
    Paul E Keck
    Department of Psychiatry, University of Cincinnati College of Medicine, and the General Clinical Research Center and Mental Health Care Line, Cincinnati Veterans Affairs Medical Center, Ohio 45267 0559, USA
    J Clin Psychiatry 67:19-24; discussion 36-42. 2006
    ..Substantial information is needed regarding the prevalence and causes of cognitive dysfunction in bipolar disorder, the effects of existing treatments on cognition, and long-term treatments to improve cognition and functioning...
  64. ncbi Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial
    Lesley M Arnold
    University of Cincinnati College of Medicine, Cincinnati, Ohio 45219, and Newton Wellesley Hospital, Newton, MA, USA
    Arthritis Rheum 56:1336-44. 2007
    ..To assess the efficacy and safety of gabapentin in patients with fibromyalgia...
  65. ncbi Emotional eating and emotional eating alternatives in subjects undergoing bariatric surgery
    Anna I Guerdjikova
    Psychopharmacology Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45267 0559, USA
    Obes Surg 17:1091-6. 2007
    ..The purpose of this study was to characterize emotional eating and its alternatives in obese patients undergoing bariatric surgery...
  66. ncbi The Texas implementation of medication algorithms update for treatment of bipolar I disorder
    Roy H Perlis
    Bipolar Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, Mass 02114, USA
    J Clin Psychiatry 66:818-20. 2005
  67. ncbi Reproductive function and risk for PCOS in women treated for bipolar disorder
    Natalie L Rasgon
    Department of Psychiatry, Stanford School of Medicine, Palo Alto, CA, USA
    Bipolar Disord 7:246-59. 2005
    ..This study examined the reproductive function and prevalence of polycystic ovary syndrome (PCOS) in women with bipolar disorder taking antimanic medications...
  68. ncbi Carbamazepine and valproate in the maintenance treatment of bipolar disorder
    Paul E Keck
    Department of Psychiatry, University of Cincinnati College of Medicine, Ohio 45267 0559, USA
    J Clin Psychiatry 63:13-7. 2002
    ..We reviewed the available data from randomized clinical trials of these agents in bipolar disorder to assess their efficacy and tolerability in the maintenance phase of illness management...
  69. ncbi A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania
    Paul E Keck
    Biological Psychiatry Program, Department of Psychiatry, University of Cincinnati College of Medicine, PO Box 670559, Cincinnati, OH 45267 0559, USA
    Am J Psychiatry 160:1651-8. 2003
    ..The authors compared the efficacy and safety of aripiprazole, a novel antipsychotic, to placebo for treatment of patients in an acute manic or mixed episode of bipolar disorder...
  70. ncbi The effect of multiple doses of cimetidine on the steady-state pharmacokinetics of quetiapine in men with selected psychotic disorders
    Stephen M Strakowski
    Bipolar and Psychotic Disorders Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Ohio 45267 0559, USA
    J Clin Psychopharmacol 22:201-5. 2002
    ..No serious adverse events were observed during quetiapine treatment. No clinically relevant alterations in quetiapine pharmacokinetics were observed after cimetidine coadministration in patients with psychotic disorders...
  71. ncbi Bipolar depression: a new role for atypical antipsychotics?
    Paul E Keck
    Psychopharmacology Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45267 0559, USA
    Bipolar Disord 7:34-40. 2005
    ..001 versus placebo). These initial findings suggest that atypical antipsychotics may prove to be important future treatments for patients with bipolar depression...
  72. ncbi Evaluation and management of breakthrough depressive episodes
    Paul E Keck
    Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, USA
    J Clin Psychiatry 65:11-5. 2004
    ..Combination therapy with a mood stabilizer and an atypical antipsychotic may also be effective in managing bipolar depressive episodes...
  73. ncbi A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia
    Lesley M Arnold
    Women s Health Research Program, Department of Psychiatry, University of Cincinnati Medical Center, Cincinnati, Ohio 45267 0559, USA
    Am J Med 112:191-7. 2002
    ..To assess the efficacy of fluoxetine in the treatment of patients with fibromyalgia...
  74. ncbi Bipolar depression: best practices for the hospitalized patient
    Paul E Keck
    Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH, USA
    CNS Spectr 12:1-13. 2007
    ..The onset and severity of bipolar depression, prevalence of substance abuse, psychosocial treatment options, and clinical issues for the long-term treatment of bipolar depression are also discussed...
  75. ncbi Bipolar depression: best practices for the outpatient
    Paul E Keck
    Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH, USA
    CNS Spectr 12:1-14. 2007
    ..Two case studies are presented to elucidate the best practices for the varying clinical states of bipolar disorder...
  76. ncbi Atypical antipsychotics in the treatment of bipolar disorder
    Stephen M Strakowski
    Department of Psychiatry, University of Cincinnati College of Medicine, PO Box 670559, Cincinnati, OH 45267 0559, USA
    Expert Opin Pharmacother 4:751-60. 2003
    ..Atypical antipsychotics offer different side effect profiles than older antipsychotics, which may be of benefit for some patients. Consequently, atypical antipsychotics provide an important treatment option for bipolar patients...
  77. ncbi Redefining mood stabilization
    Paul E Keck
    Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45267 0559, USA
    J Affect Disord 73:163-9. 2003
    ..No available agent meets the criteria for a comprehensive mood-stabilizer, although lithium comes the closest...
  78. ncbi Moderators of placebo response to antipsychotic treatment in patients with schizophrenia: a meta-regression
    Jeffrey A Welge
    Biological Psychiatry Program, Department of Psychiatry, University of Cincinnati College of Medicine, 231 Bethesda Avenue, P O Box 670559, Cincinnati, OH 45267 0559, USA
    Psychopharmacology (Berl) 166:1-10. 2003
    ..Therefore, it is of great importance to identify factors that moderate response to placebo in such trials...
  79. ncbi Severity of bipolarity in hospitalized manic adolescents with history of stimulant or antidepressant treatment
    Cesar A Soutullo
    University of Cincinnati, Department of Psychiatry, Biological Psychiatry and Psychotic and Bipolar Disorders Research Programs, PO Box 670559, 231 Bethesda Avenue, Cincinnati, OH 45267 0559, USA
    J Affect Disord 70:323-7. 2002
    ..Childhood bipolarity (BP) and ADHD frequently co-occur, these children often receive stimulants...
  80. ncbi Memantine efficacy and safety in patients with acute mania associated with bipolar I disorder: a pilot evaluation
    Paul E Keck
    Psychopharmacology Research Program, Department of Psychiatry, University of Cincinnati, College of Medicine, Cincinnati, OH, USA
    Clin Neuropharmacol 32:199-204. 2009
    ..Evaluate the efficacy and tolerability of memantine (20, 30, and 40 mg/d) in the acute treatment of adults with bipolar I disorder hospitalized for mania...
  81. ncbi Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications
    Paul E Keck
    Department of Psychiatry, University of Cincinnati College of Medicine, Ohio 45267 0559, USA
    J Clin Psychiatry 63:3-11. 2002
    ..We reviewed the clinical pharmacodynamics and pharmacokinetics of these agents to provide a summary of these properties relevant to clinical practice...
  82. ncbi Predictors of response to treatment of acute bipolar manic episodes with divalproex sodium or placebo in 2 randomized, controlled, parallel-group trials
    Jeffrey A Welge
    Division of Clinical Neuroscience, Psychopharmacology Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati Veterans Affairs Medical Center, Cincinnati, OH, USA
    J Clin Psychopharmacol 24:607-12. 2004
    ..Stratification on the basis of these prognostic factors may improve the power of future trials for the treatment of acute mania and may help explain patient response to treatment...
  83. ncbi Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: A retrospective, population-based, case-control study
    Jeff J Guo
    College of Pharmacy, University of Cincinnati Medical Center, Cincinnati, Ohio 45267 0004, USA
    J Clin Psychiatry 67:1055-61. 2006
    ..Drug-induced diabetes onset has not been adequately quantified in patients with bipolar disorder, although atypical antipsychotics have been widely used as new mood stabilizers...
  84. ncbi Neuroleptic malignant syndrome
    Jeffrey R Strawn
    University of Cincinnati, Department of Psychiatry, College of Medicine, Box 670559, Cincinnati, OH 45267 0559, USA
    Am J Psychiatry 164:870-6. 2007
  85. ncbi Long-term management strategies to achieve optimal function in patients with bipolar disorder
    Paul E Keck
    Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
    J Clin Psychiatry 67:e17. 2006
    ..This review discusses treatment strategies for the long-term management of bipolar disorder and functional outcome measures associated with these treatments...
  86. doi Atypical neuroleptic malignant syndrome: diagnostic controversies and considerations
    Lara S Picard
    Division of Pharmacy Practice and Administrative Sciences, College of Pharmacy, University of Cincinnati, Cincinnati, OH, USA
    Pharmacotherapy 28:530-5. 2008
    ..In patients receiving any antipsychotic, clinicians should carefully evaluate any features of NMS and should not prematurely exclude a diagnosis of NMS in cases where severe rigidity or hyperthermia is not initially apparent...
  87. ncbi A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression
    Sara A Corya
    Lilly Research Laboratories, Indianapolis, Ind, USA
    J Clin Psychiatry 67:798-806. 2006
    ..The present analyses examined the efficacy and safety of longer term treatment with olanzapine-fluoxetine combination or olanzapine monotherapy in a 6-month open-label extension study...
  88. ncbi Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials
    Roy H Perlis
    Bipolar Research Program, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 67:509-16. 2006
    ..However, there are no published comparisons of individual atypical antipsychotics for mania...
  89. ncbi Economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in mania. Results from a randomized controlled trial
    Madhav A Namjoshi
    Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, IN, USA
    J Affect Disord 69:109-18. 2002
    ..The objectives of this study were to determine the economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in patients diagnosed with mania...
  90. ncbi A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression
    Eileen B Brown
    Lilly Research Laboratories, Indianapolis, IN, USA
    J Clin Psychiatry 67:1025-33. 2006
    ..Determine the efficacy and tolerability of olanzapine/fluoxetine combination (OFC) for treatment of acute bipolar I depression compared with lamotrigine...
  91. ncbi Lower switch rate in depressed patients with bipolar II than bipolar I disorder treated adjunctively with second-generation antidepressants
    Lori L Altshuler
    Dept of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, 300 UCLA Medical Plaza, Suite 1544, Box 957057, Los Angeles, CA 90095 7057
    Am J Psychiatry 163:313-5. 2006
    ..The authors compared the switch rate into hypomania/mania in depressed patients treated with second-generation antidepressants who had either bipolar I or bipolar II disorder...
  92. ncbi Extended-release carbamazepine capsules as monotherapy in bipolar disorder : pooled results from two randomised, double-blind, placebo-controlled trials
    Richard H Weisler
    Department of Psychiatry and Behavioral Science, Duke University, Raleigh, North Carolina 27609, USA
    CNS Drugs 20:219-31. 2006
    ..By pooling data from these two trials, a more highly powered analysis of the efficacy and safety of CBZ-ERC in bipolar I disorder could be conducted...
  93. ncbi Number needed to treat and time to response/remission for quetiapine monotherapy efficacy in acute bipolar depression: evidence from a large, randomized, placebo-controlled study
    John Cookson
    The Department of Psychiatry, Royal London Hospital, London, UK
    Int Clin Psychopharmacol 22:93-100. 2007
    ..2%, quetiapine 300 mg/day: 3.9, and placebo: 3.9%). In conclusion, quetiapine compared with placebo significantly reduces time to response and remission compared with placebo, and has a favorable number needed to treat...
  94. ncbi Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers
    Gabriele S Leverich
    Biological Psychiatry Branch, National Institutes of Mental Health, Bldg 10 Room 3S239, 10 Center Drive, MSC 1272, Bethesda, MD 20892 1272, USA
    Am J Psychiatry 163:232-9. 2006
    ..The authors examined the comparative risks of switches in mood polarity into hypomania or mania during acute and continuation trials of adjunctive antidepressant treatment of bipolar depression...
  95. ncbi Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial
    Richard H Weisler
    Department of Psychiatry and Behavioral Sciences, Duke University, 700 Spring Forest, Suite 125, Raleigh, NC 27609, USA
    J Clin Psychiatry 66:323-30. 2005
    ..In the present study, we further evaluated the efficacy and safety of monotherapy with beaded, extended-release carbamazepine capsules (ERC-CBZ) in patients with bipolar I disorder experiencing manic or mixed episodes...
  96. ncbi Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial
    Robert M A Hirschfeld
    Department of Psychiatry and Behavioral Sciences, University of Texas Medical Branch, Galveston, TX 77555, USA
    Am J Psychiatry 161:1057-65. 2004
    ..This study evaluated the efficacy and safety of risperidone monotherapy in the treatment of acute bipolar mania...
  97. ncbi Preliminary observations on the effectiveness of levetiracetam in the open adjunctive treatment of refractory bipolar disorder
    Robert M Post
    Biological Psychiatry Branch, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    J Clin Psychiatry 66:370-4. 2005
    ..Given the effectiveness of a range of other anticonvulsants in bipolar disorder, we sought to evaluate levetiracetam in patients with treatment-resistant illness...
  98. ncbi Correlates of 1-year prospective outcome in bipolar disorder: results from the Stanley Foundation Bipolar Network
    Willem A Nolen
    Altrecht Institute for Mental Health Care, Utrecht, The Netherlands
    Am J Psychiatry 161:1447-54. 2004
    ..The purpose of the study was to examine potential correlates of outcome in patients treated for bipolar disorder...
  99. ncbi A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression
    Joseph R Calabrese
    University Hospitals of Cleveland and Case University School of Medicine, 11400 Euclid Ave, Suite 200, Cleveland, OH 44106, USA
    Am J Psychiatry 162:1351-60. 2005
    ..There is a major unmet need for effective options in the treatment of bipolar depression...
  100. ncbi Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial
    Steven G Potkin
    Neuropsychiatric Center, University of California Irvine, 101 City Drive South, Bldg 3, Orange, CA 92868 3298, USA
    J Clin Psychopharmacol 25:301-10. 2005
    ..In an earlier 21-day, placebo-controlled trial, ziprasidone was efficacious in improving symptoms of mania and was well tolerated. To confirm these results, a similarly designed 21-day trial was conducted...
  101. ncbi Olanzapine versus placebo in acute mania: treatment responses in subgroups
    Ross J Baldessarini
    International Consortium for Bipolar Disorder Research, Department of Psychiatry and Neuroscience Program, Harvard Medical School, Boston, MA, USA
    J Clin Psychopharmacol 23:370-6. 2003
    ..5-1.7, all P < 0.01). These well-powered comparisons of subgroups of interest indicate broad efficacy of olanzapine in the treatment of acute mania...